Consistency Of NGS And IHC In Detecting ALK Positive Non-small Cell Lung Cancer And Its Efficacy Of Crizotinib

Objective Ventana D5F3 Immunohistochemistry(IHC)is the main detection method for Anaplastic lymphoma kinase(ALK)and can be used as a concomitant diagnosis for ALK detection.Currently,there is a lack of NGS detection guidance The effective study of crizotinib treatment,so this article aims to explore the consistency of NGS and Ventana D5F3 IHC detection of ALK positive non-small cell lung cancer(NSCLC)and the observation of the efficacy of crizotinib.Methods From March 2015 to December 2018,To retrospectively collect 237 patients with non-small cell lung cancer with ALK positive in Hunan Cancer Hospital,and 86 cases patients who met the conditions were found through screening.NGS and Ventana IHC separately detect ALK,and then use two methods to test together for further verification,divided into three groups,Group A,NGS and Ventana IHC test ALK positive;Group B,NGS test ALK positive,Ventana IHC test ALK negative;Group C,NGS test ALK negative,Ventana IHC test ALK positive.Observe the progression-free survival(PFS),Objective Response Rate(ORR)and Disease Control Rate(DCR)after treatment with crizotinib.According to statistical data,P Values<0.05 are meaningful.Results A total of 86 patients with advanced NSCLC with ALK positive detected by Ventana IHC and NGS were collected(mean age 52.5 years,60.4% female,73.3% without smoking history,100% advanced lung adenocarcinoma type).79 ALK positive patients tested using NGS(91.9%);72 ALK positive patients tested using Ventana IHC(83.7%);65 ALK positive patients tested using NGS and Ventana IHC(75.6%);14 ALK positive patients tested using NGS and negative tested using IHC(16.3%);7 ALK positive patients tested using IHC and negative tested using NGS(8.1%).The average PFS after treatment with crizotinib in groupsA,B,andC(15.3mvs11.8mvs10.8m,p=0.12),ORR(89.2%vs85.7%vs85.7%,p=0.85)and DCR(98.5%vs100%vs100%,p= 0.95).Conclusion1.NGS and Ventana IHC test ALK-positive NSCLC patients have high consistency,NGS and Ventana IHC detection methods have no difference in the efficacy of crizotinib,indicating that NGS detection can also guide crizotinib treatment.